Retrospective study on the differences of efficacy of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor treatment in advanced lung adenocarcinoma patients harboring L858R mutation

doi:10.3877/cma.j.issn.1674-6902.2017.01.005

Abstract

Abstract:

Objective

To explore the differences of efficacy of the chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor treatment in advanced lung adenocarcinoma patients harboring exon 21 mutation.

Methods

The clinical characteristic of advanced lung adenocarcinoma harboring EGFR 21 L858R mutation receiving first-line chemotherapy and EGFR-TKI treatment in Xinqiao hospital from Jan 2010 to Dec 2015 were studied. The differences between the clinical indicators of the two groups, such as objective response rates (ORR), disease control rates(DCR), progression free survival(PFS), overall survival(OS) were analyzed.

Results

①The data of 68 patients were collected including 40 chemotherapy and 28 EGFR-TKI. Baselines of sex, age, smoking status, ECOG PS between the two groups were consistent (P>0.05) . ②The ORR of the two groups were 45% and 17.9%(P=0.020), the DCR of the two groups were 95% and 71.4%(P=0.012). The PFS of the two groups were 9.901 and 6.746 months (P=0.045), the OS of the two groups were 21.738 and 23.611 months (P=0.378).

Conclusions

Compared with EGFR-TKI, the patients of advanced lung adenocarcinoma treated with chemotherapy had significant advantage of ORR, DCR and PFS, no difference on OS.

Key words: Epidermal growth factor receptor mutation, Lung adenocarcinoma, Chemotherapy, Targeted molecular therapy, Clinical efficacy, Retrospective analysis

Meng Luo, Yu Xu, Yide Hu. Retrospective study on the differences of efficacy of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor treatment in advanced lung adenocarcinoma patients harboring L858R mutation[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(01): 20-24.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.01.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I01/20

Figures/Tables 4

References 21

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
3	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
4	2015美国国家综合癌症网络(NCCN)指南：肺癌的全身治疗[J]．中国全科医学，2015(18): 2126.
5	Gridelli C, Ardizzoni A, Douillard JY, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the Italian association of thoracic oncology[J]. Lung cancer, 68(3): 319-331.
6	Kuan FC, Kuo LT, Chen MC, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis[J]. Br J Cancer, 2015, 113(10): 1519-1528.
7	Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): 958-967.
8	Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. Lancet Oncol, 2015, 16(2): 141-151.
9	Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2006, 12(13): 3908-3914.
10	Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung pleurthymus and heart[M]. Lyon: IARC Press, 2004.
11	钱桂生. 为提高我国呼吸系统疾病的诊治水平而努力[J/CD]. 中华肺部疾病杂志(电子版), 2012, 5(1): 1-3.
12	邹晶，徐兴祥，王大新，等. 肺癌放化疗"实时"疗效评估方法的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2013, 6(4): 360-363.
13	Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis[J]. PLoS One, 2014, 9(9): e107161.
14	Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: The achilles 'heal’ of lung cancers[J]. Trends Mol Med, 2004, 10(10): 481-486.
15	Yu HA, Arcila ME, Hellmann MD, et al. Poor response to erlotinib in patients with tumors containing baselineEGFR T790M mutations found by routine clinical molecular testing[J]. Ann Oncol, 2014, 25(2): 423-428.
16	Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer[J]. Clin Cancer Res, 2005, 11(10): 3750-3757.
17	Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer Sci, 2007, 98(12): 1817-1824.
18	Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response[J]. Clin Cancer Res, 2008, 14(15): 4877-4882.
19	Arrieta O, Cardona AF, Corrales L, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer[J]. Lung Cancer, 2015, 87(2): 169-175.
20	Ellis PM, Coakley N, Feld R, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review[J]．Curr Oncol, 2015, 22(3): 183-215.
21	Shi L, Tang J, Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials[J]. Lung Cancer, 2014, 83(2): 231-239.

临床资料		化疗(n＝40)	靶向治疗(n＝28)	P值
性别		?	?	?
?	男	20	17	0.383
?	女	20	11	?
年龄		?	?	?
?	≤58岁	24	13	0.269
?	≥58岁	16	15	?
吸烟史		?	?	?
?	有	15	8	0.444
?	无	25	20	?
ECOG PS		?	?	?
?	0分	5	3	0.228
?	1分	35	23	?
?	2分	0	2	?
临床分期		?	?	?
?	ⅢB期	2	3	0.396
?	Ⅳ期	38	25	?

临床资料		化疗(n＝40)	靶向治疗(n＝28)	P值
性别		?	?	?
?	男	20	17	0.383
?	女	20	11	?
年龄		?	?	?
?	≤58岁	24	13	0.269
?	≥58岁	16	15	?
吸烟史		?	?	?
?	有	15	8	0.444
?	无	25	20	?
ECOG PS		?	?	?
?	0分	5	3	0.228
?	1分	35	23	?
?	2分	0	2	?
临床分期		?	?	?
?	ⅢB期	2	3	0.396
?	Ⅳ期	38	25	?

治疗方式	治疗效果				客观缓解率	疾病控制率
治疗方式	PR	SD	PD	合计	客观缓解率	疾病控制率
化疗	18	20	2	40	45.00	95.00
靶向治疗	5	15	8	28	17.86	71.43
P值	?	?	?	0.020	0.012	?

治疗方式	治疗效果				客观缓解率	疾病控制率
治疗方式	PR	SD	PD	合计	客观缓解率	疾病控制率
化疗	18	20	2	40	45.00	95.00
靶向治疗	5	15	8	28	17.86	71.43
P值	?	?	?	0.020	0.012	?

[1]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[2]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[3]	Hua Zhang, Yu Sun, Shijian Xiang, Yingmei Li, Xiaoqun Wang. Research on chemosensitivity evaluation using circulating tumor cells in advanced gastrointestinal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 422-425.
[4]	Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[5]	Tao Chen, Hong Luo, JingJun Zhou. Risk factors of acute adverse reactions in elderly patients with esophageal cancer treated with radiotherapy alone and concurrent radiotherapy and chemotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 405-407.
[6]	Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[7]	Binkui Li. Conversion therapy for unresectable intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 511-516.
[8]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[9]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[10]	Lijiao Jiang, Feng Zhang, Yuping Zhou. Clinical efficacy observation of treating elderly patients with acute non-variceal upper gastrointestinal hemorrhage using the MDT model [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 520-524.
[11]	Jingxu Zhang, Defang Li, Shangke You, Yutian Zhang. Clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 289-293.
[12]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[13]	Jun Dong, Fangfang Wu. Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 236-240.
[14]	Jun Zhao, Chaojie Li, Jia Li. Curative effect of rabeprazole combined with Kangfuxin solution on duodenal ulcer with positive Helicobacter pylori infection [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 254-258.
[15]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.

Please choose a citation manager

Content to export